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ABSTRACT
Background
Trials in macaque models play an essential role in the evaluation of biomedical interventions
that aim to prevent HIV infection, such as vaccines, microbicides, and systemic chemo-
prophylaxis. These trials are usually conducted with very high virus challenge doses that result
in infection with certainty. However, these high challenge doses do not realistically reflect the
low probability of HIV transmission in humans, and thus may rule out preventive interventions
that could protect against ‘‘real life’’ exposures. The belief that experiments involving
realistically low challenge doses require large numbers of animals has so far prevented the
development of alternatives to using high challenge doses.
Methods and Findings
Using statistical power analysis, we investigate how many animals would be needed to
conduct preclinical trials using low virus challenge doses. We show that experimental designs
in which animals are repeatedly challenged with low doses do not require unfeasibly large
numbers of animals to assess vaccine or microbicide success.
Conclusion
Preclinical trials using repeated low-dose challenges represent a promising alternative
approach to identify potential preventive interventions.
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Worldwide approximately 40 million people are infected
with HIV, and more than 3 million people died of AIDS last
year alone [1]. Unfortunately, numerous obstacles to provid-
ing effective antiretroviral treatment to the majority of
infected individuals in resource-poor countries exist. The
development of a vaccine or other preventive biomedical
intervention therefore bears the greatest hope to curb the
rampant HIV epidemic [2].
Research on HIV vaccines and prevention relies strongly
on preclinical studies in macaque models for the identiﬁca-
tion and evaluation of potential vaccines or prophylactic
treatment strategies [3]. Initially, the goal was to use animal
trials to screen for preventive interventions that induce
sterilizing immunity (i.e., protection against infection) since
this would clearly be the most effective way to contain the
AIDS pandemic. Unfortunately, most of the vaccine ap-
proaches assessed to date in animal studies have failed to
induce sterilizing immunity [4–7], although some prophylac-
tic approaches were found to reduce susceptibility to
infection [8–12]. As a result of this shortcoming, vaccine
candidates are at present primarily examined with regard to
their effects on set point viremia, disease progression, and
their general immunogenicity, rather than with regard to the
degree of protection against infection they confer. However,
the inference as to the degree of sterilizing immunity from
the level of immunogenicity is limited by our lack of
knowledge about the mechanisms of protection against
infection as such [13].
The inability of most vaccine candidates to induce
protection against infection in animal studies may be due,
at least in part, to unintended consequences of the design of
the animal trials, rather than to problems inherent in the
vaccination approaches themselves. In most animal studies
that seek to test the efﬁcacy of a given preventive
intervention, very high challenge doses are used, typically of
approximately 10–100 times the infectious dose at which 50%
of the animals become infected (ID50). The motivation for
using such high challenge doses is mostly practical: the
experimenter wants to ascertain infection success in unvacci-
nated/untreated animals, which can then be compared to the
hopefully lower infection success in vaccinated/treated
animals. There are, however, concerns with using high
challenge doses. Firstly, the extremely high probability of
infection in high-dose challenge studies conﬂicts with the low
transmission rate of HIV per sex act [14–17]. Although it has
been argued that transmission rates may be higher under
some circumstances (such as during acute infection or when
other infections of the genital tract are present) than the
estimates obtained from discordant couple studies suggest
(e.g., the recent study by Pilcher et al. [18]), transmission of
HIV during one sex act surely does not occur with certainty.
Secondly, protection against high-dose virus challenges may
be more difﬁcult to achieve because the use of high challenge
doses makes stochastic extinctions that can play an important
role in early control of the infection [19] very unlikely. Thus,
standard high-dose challenge studies may rule out preventive
intervention strategies that could protect against infections
following ‘‘real life’’ exposures.
The problems of using high virus doses in animal studies
can be illustrated by the discrepancy between the protection
zidovudine (AZT) confers in animals and humans. Whereas
macaques [20,21] and mice [22] were not protected from
infection with high challenge doses by zidovudine (a relatively
weak antiretroviral drug when used in monotherapy), clinical
studies surprisingly showed that two-thirds of perinatal
infections (i.e., mother-to-child transmissions during birth)
can be prevented by zidovudine administration [23]. It is
important to note that the use of zidovudine to prevent
perinatal HIV infection is a biomedical intervention aiming
to protect from infection, whereas zidovudine is most
commonly used as a therapeutic agent after infection. This
example suggests that there is a need for experimental
designs that allow the assessment of the protection against
infection with lower, and thus more realistic, challenge doses.
The belief that experiments involving realistically low
challenge doses require unfeasibly large numbers of animals
has prevented the development of low-dose challenge models.
In this theoretical study, we show that, contrary to this widely
held belief, low-dose challenge experiments can be designed
such that they do not require large numbers of animals. Using
statistical power analysis, we compare two experimental
designs (see Figure 1): (i) a single low-dose challenge design
in which each animal is challenged only once, and (ii) a
repeated low-dose challenge design in which each animal is
challenged until it is infected or a predetermined maximum
number of challenges is reached. We ﬁnd that the repeated
low-dose challenge design does not require unfeasibly large
numbers of animals.
In the following, we are going to discuss the case of
assessing whether a vaccine candidate induces sterilizing
immunity. All the considerations in this article, however,
apply equally to other preventive interventions, such as
microbicides.
Methods
To assess the quality of the single and the repeated low-
dose challenge designs, we conducted a statistical power
analysis. The statistical power of an experimental design is
deﬁned as the probability that an effective vaccine or
treatment is correctly determined to be effective. This
analysis consists of simulating the experiments, evaluating
them, and then repeating this procedure thousands of times
to estimate the statistical power of a given experimental
design.
Simulation of Single Low-Dose Challenge Experiments
In our simulations of the single low-dose challenge experi-
ments, we assume that we have n unvaccinated control
animals and n vaccinated animals.
In the control group, we simulate single challenges of each
animal with the ID50 by performing n Bernoulli trials with a
probability of success of pc ¼ 0.5. The probability of success
corresponds to the probability with which an animal becomes
infected after a single challenge. (By assuming the same
probability pc for each animal, we ignore potential between-
animal variation of the susceptibility to infection. This
assumption will be relaxed below.) The results of these trials
can be written as a vector xc, the entries of which were either
zero (uninfected) or one (infected):
PLoS Medicine | www.plosmedicine.org August 2005 | Volume 2 | Issue 8 | e249 0799
Low-Dose Virus Challengesxc ¼
xc1
xc2
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.
xcn
0
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;xci 2f 0;1g;i ¼ 1;:::;n ð1Þ
By summing over the elements of xc, we obtain the number of
infected animals in the control group, ic:
ic ¼
X n
i¼1
xci ð2Þ
In the vaccinated group, we simulate single challenges with
the ID50 similarly to the control group by performing
Bernoulli trials. However, we assume that, because of
vaccination, the probability of infection (or success) in the
vaccinated group, pv, is lower than that in the control
animals, pc. The relation of pv to the effect of the vaccine on
the susceptibility of the host, VES, is given by:
pv ¼ pcð1   VESÞ¼ð 1   VESÞ=2; 0   VES   1 ð3Þ
The results of these Bernoulli trials can again be written as a
vector xv, and summing the elements of xv we obtain the
number of infected animals in the vaccinated group, iv.
The outcome of the simulated experiment can then be
summarized in a contingency table as shown in Table 1. On
this contingency table, we perform a standard one-tailed
Fisher’s exact test [24] to assess whether the fraction of
infected animals in the vaccinated group is signiﬁcantly lower
than that in the control group.
Simulation of Repeated Low-Dose Challenge Experiments
In our simulations of the repeated low-dose challenge
experiments, we once more assume that we have n unvacci-
nated control animals and n vaccinated animals.
We again simulate challenges of each control animal with
the ID50 by performing Bernoulli trials with a probability of
success of pc¼0.5. Unlike in the simulations of the single low-
dose challenge experiments, however, we now repeatedly
challenge each animal until it is infected or until a maximum
number of challenges, Cmax, has been performed. We assume
that the probability of infection pc is independent of how
often an animal has been challenged before. The results of
these repeated Bernoulli trials can be written as two vectors,
yc, which contains the number of challenges that have been
performed on each animal:
yc ¼
yc1
yc2
. .
.
ycn
0
B B B @
1
C C C A
;yci 2f 0;1;...;Cmaxg;i ¼ 1;...;n ð4Þ
and sc, which contains information on whether a given animal
is uninfected (zero) or infected (one):
sc ¼
sc1
sc2
. .
.
scn
0
B B B @
1
C C C A
;sci 2f 0;1g;i ¼ 1;...;n ð5Þ
By summing over yc, we obtain the total number of challenges
performed in the control group, gc:
gc ¼
X n
i¼1
yci ð6Þ
And, by summing over sc, we obtain the number of infected
animals in the control group, ic:
ic ¼
X n
i¼1
sci ð7Þ
To simulate repeated low-dose challenges in the vaccinated
group, we perform repeated Bernoulli trials with a prob-
ability of success pv. For a given vaccine efﬁcacy VES,p v is
determined by equation 3. Analogously to the control group,
the results of these repeated Bernoulli trials can be written as
two vectors, yv and sv, and summing the elements of these two
vectors yields the total number of challenges performed in
Figure 1. Single and Repeated Low-Dose Challenge Designs
Figure shows designs for single (A) and repeated (B) low-dose challenge designs. Small arrows denote challenges, and white and red symbols denote
uninfected and infected animals, respectively.
DOI: 10.1371/journal.pmed.0020249.g001
Table 1. Contingency Table of a Single Low-Dose Challenge
Experiment
Group Number of Individuals
Infected Uninfected
Control group ic n   ic
Vaccinated group iv n   iv
DOI: 10.1371/journal.pmed.0020249.t001
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Low-Dose Virus Challengesthe vaccinated group, gv, and, the number of infected animals
in the vaccinated group, iv.
As in the case of the single low-dose challenge design, the
outcome of the simulated experiment can be summarized in a
contingency table (Table 2). To assess whether the fraction of
infected animals in the vaccinated group is signiﬁcantly lower
than that in the control group, we again perform a one-tailed
Fisher’s exact test [24]. In general, the number of challenges,
gc and gv, is larger than the number of animals per group, n.
This increase of numbers in the contingency table leads to
increased statistical power of the repeated low-dose challenge
design. To analyze the outcome of the simulated repeated
low-dose challenge experiments, we chose to use Fisher’s
exact test rather than a more obvious Cox proportional
hazards model because the latter depends on large sample
asymptotics while we were interested in cases of small
numbers of experimental animals.
Heterogeneity in Infection Probabilities
In our mathematical description of challenge experiments,
we have assumed that animals within each group have equal
infection probabilities—pc and pv, for the control and
vaccinated groups, respectively. To simulate potential ani-
mal-to-animal variation in susceptibility to infection, we
relaxed this assumption and assigned individual infection
probabilities to each animal.
The individual infection probabilities are drawn from a b-
distribution, which is often used as a prior distribution for
binomial proportions. The b-distribution has two shape
parameters, a and b. Its probability density is given by
PðxÞ¼
Cða þ bÞ
CðaÞCðbÞ
xa 1ð1   xÞ
b 1 ð8Þ
and its mean and variance are
l ¼
a
a þ b
ð9Þ
r2 ¼
ab
ða þ bÞ
2ða þ b þ 1Þ
ð10Þ
We assume that l ¼ pc in the control group and l ¼ pv ¼ (1  
VES)pc in the vaccinated group. Further, we assume that the
coefﬁcients of variation, CV ¼ r/l, of the distributions in the
two groups are equal. With these assumptions, we can rewrite
the two shape parameters of the b-distribution, a and b,i n
terms of the infection probability, p, and the coefﬁcient of
variation, CV:
a ¼
1  ð 1 þ CV2Þp
CV2 ð11Þ
b ¼
ð1 þ CV2Þp2  ð 2 þ CV2Þp þ 1
CV2p
ð12Þ
Hereby, p ¼ pc for the control group and p ¼ pv ¼ (1   VES)pc
for the vaccinated group.
To incorporate potential heterogeneity in susceptibility
into the virtual low-dose challenge experiments, we replaced
the probability of success in the Bernoulli trials (see above)
with the individual infection probabilities.
Power Analysis
To calculate the statistical power of the single and the
repeated low-dose challenge designs, we performed 100,000
such simulated experiments for a given number, n, of animals
per group. The statistical power can be estimated as the
fraction of simulated experiments in which the vaccine is
found to be signiﬁcantly efﬁcacious (signiﬁcance level a ¼
0.05). We estimated the statistical power for the number of
animals per group, n, ranging from one to 20, and for vaccine
efﬁcacies VES¼0.67, 0.8, and 0.9. The power analysis outlined
above was implemented in the R Language of Statistical
Computing [25]. An R-script that performs the power analysis
presented here is provided as Protocol S1.
For large numbers of animals per group, n, the statistical
power can be approximated using asymptotic theory. For the
single low-dose challenge design the power is approximately
(e.g., [26], p. 240):
1   U za  
pc   pv   1=n
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pcð1 pcÞ
n þ
pvð1 pvÞ
n
r
0
B B @
1
C C A ð13Þ
Hereby, U denotes the cumulative normal distribution,
UðxÞ¼
1
ﬃﬃﬃﬃﬃﬃ
2p
p
Z x
 ‘
e n
2=2dn ð14Þ
and za is the standard normal deviate associated with the one-
tailed probability a (the signiﬁcance level). Furthermore, pc
and pv denote the infection probabilities of animals in the
control and vaccinated groups, respectively, and n the
number of animals per group. The term 1/n in the numerator
is the continuity correction [27,28].
For the repeated low-dose challenge design, the number of
challenges is not the same as the number of animals, n, but is a
random variable. The number of challenges for each
individual is geometrically distributed with a maximum of
Cmax. The expected number of challenges in the control
group, hgci, and the vaccinated group, hgvi are
hgci¼
X Cmax 1
k¼0
nð1   pcÞ
k ¼
n
pc
ð1  ð 1   pcÞ
CmaxÞð 15Þ
and
hgvi¼
X Cmax 1
k¼0
nð1   pvÞ
k ¼
n
pv
ð1  ð 1   pvÞ
CmaxÞð 16Þ
Substituting the expected number of challenges for the actual
Table 2. Contingency Table of a Repeated Low-Dose Challenge
Experiment
Group Number of Individuals
Infected Uninfected
Control group ic gc   ic
Vaccinated group iv gv   iv
DOI: 10.1371/journal.pmed.0020249.t002
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Low-Dose Virus Challengesnumber, we can approximate the statistical power of the
repeated low-dose challenge design as
1   U za  
pc   pv   c
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pcð1 pcÞ
hgci þ
pvð1 pvÞ
hgvi
r
0
B B @
1
C C A ð17Þ
Hereby, c¼(1/hgciþ1/hgvi)/2 is the continuity correction. For
Cmax ¼ 1, equation 17 reduces to equation 13. Because the
approximation in equation 17 involves the substitution of a
random variable with its expectation, it is less accurate than
the approximation for the power of the single low-dose
challenge design in equation 13. The R-script provided as
Protocol S1 also contains a function that calculates the
statistical power using equation 17.
Results
Single Low-Dose Challenge Design Requires Large
Numbers of Animals
How would we measure protection against infection in a
low-dose challenge model? The most straight-forward design
would involve a large number of hosts, some vaccinated and
some unvaccinated. After challenge with a low dose, one
would determine the fraction of infected hosts in vaccinated
and unvaccinated groups, and assess whether there is a
statistically signiﬁcant difference in the fractions (see Figure
1A).
To assess how many animals would be required in a single
low-dose challenge experiment, we performed a statistical
power analysis (see Methods). The statistical power of an
experimental design is deﬁned as the probability that, in an
experiment with an effective vaccine, the vaccine is correctly
determined to be effective. Obviously the power depends on
the efﬁcacy of the vaccine (which is called the ‘‘effect size’’ in
the context of power analysis) and the number of host
animals used in the experiment. In the power analysis we
performed, we assumed that we had equal numbers of
unvaccinated and vaccinated animals, and that all animals
within a group were equally susceptible to infection. Lastly,
we assumed that the vaccine was ‘‘leaky’’ [29,30], i.e., that the
susceptibility of vaccinated animals was by a constant factor
lower than the susceptibility of the unvaccinated control
animals.
In virtual experiments, we then challenged each (virtual)
animal once with a challenge dose of one ID50, the dose at
which on average 50% of the unvaccinated animals become
infected after a single challenge. Using a one-sided Fisher’s
exact test, we tested whether the fraction of infected animals
in the vaccinated group was signiﬁcantly lower than in the
control group. Performing 100,000 such virtual experiments
for a given number n animals per group, we estimated the
statistical power as the fraction of virtual experiments that
yielded signiﬁcant results (signiﬁcance level a ¼ 0.05).
The result of this power analysis is shown by the green
curves in Figure 2. We calculated the power for vaccine
efﬁcacies of 67%, 80%, and 90%. We found that, even for the
highest vaccine efﬁcacy of 90%, the single low-dose challenge
design required more than 20 animals per group to reach a
statistical power of 95%. Thus, the single low-dose challenge
design is not feasible, or at least not practical, to assess the
efﬁcacy of a vaccine or other preventive interventions in
animals.
Repeated Low-Dose Challenge Design Does Not Require
Large Numbers of Animals
We propose an alternative design involving repeated
challenges of individual animals with low doses, which
circumvents the disadvantage of the single low-dose challenge
design that large numbers of host individuals are required.
Repeated challenges effectively ‘‘recycle’’ host animals, thus
increasing the statistical power of the experiment. In addition
to increasing the statistical power of the experimental design,
repeated challenges recapitulate much more realistically the
circumstances of human exposure than single challenges. In
this alternative design, the efﬁcacy of a vaccine can be
estimated by measuring the difference in the number of
challenges needed to infect vaccinated versus unvaccinated
hosts (see Figure 1B).
To show that this alternative design does not require
unfeasibly large numbers of animals, we performed a
statistical power analysis (see Methods). As for the single
low-dose design, we assumed that we had equal numbers of
unvaccinated and vaccinated animals, and that all animals
within a group were equally susceptible to infection. We
further made the important assumption that the suscepti-
bility of an individual animal was independent of how often
the animal was unsuccessfully challenged previously. This
assumption is commonly adopted in statistical models that
are used to estimate the transmission rate of HIV [14–17]. By
making this assumption, we ignored that an unsuccessful
challenge may induce some degree of immunity against
subsequent challenges. We would like to emphasize, however,
that this assumption is not crucial for our argument, unless
the degree of induced immunity is very high. Lastly, we again
assumed that the vaccine was leaky [29,30].
In virtual experiments, we then challenged the (virtual)
Figure 2. Power Analysis for the Repeated Low-Dose Challenge Design
and the Single Low-Dose Challenge Design
In our virtual experiments, we set the challenge dose equal to the ID50,
and assumed that the vaccine efficacy was 67% (dotted lines), 80%
(dashed lines), or 90% (solid lines). The graph shows the statistical power
of the repeated low-dose challenge design (black lines) and the single
low-dose challenge design (green lines) for a given number of animals
per group as determined from 100,000 virtual experiments. If the vaccine
is 90% effective, the statistical power of the repeated low-dose challenge
design is higher than 95% with only five animals per group, as compared
to only 15% for the single low-dose challenge design.
DOI: 10.1371/journal.pmed.0020249.g002
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allowed for a maximum number of 20 challenges of each
individual animal. Table 3 shows the outcome of one such
virtual experiment. We analyzed the outcome of the virtual
experiments with a one-tailed Fisher’s exact test (see
Methods). We again estimated the statistical power by
performing 100,000 such virtual experiments for a given
number n animals per group.
Figure 2 shows the statistical power of the repeated low-
dose challenge design as a function of the number of animals
per group for varying vaccine efﬁcacies (black lines), and
compares it to the statistical power of the single low-dose
challenge design (green lines). The statistical power achieved
with the repeated low-dose challenge design is generally
higher than that achieved with the single low-dose challenge
design. If the vaccine is 90% effective (VES ¼ 0.9), i.e., it
reduces the susceptibility by a factor of ten, the number of
animals per group could be as low as ﬁve to achieve more
than 95% statistical power. In contrast, in single low-dose
challenge experiments with the same number of animals per
group the statistical power is only 15%. Thus, repeated low-
dose challenge experiments are expected to require far fewer
animals than single low-dose challenge experiments.
How Often Should Virus Challenges Be Repeated?
To investigate how the maximum number of challenges
affected the statistical power, we plotted the power against
Cmax for trials involving six and 12 animals per group (Figure
3). We found that the power increases with Cmax, but for high
Cmax the returns diminished considerably. The lower the
number of animals per group, n, the higher the maximum
number of challenges, Cmax, for which the power effectively
saturated. Even for low numbers of animals per group, n,
however, the maximum number of challenges, Cmax, needed to
unfold the full potential of the repeated low-dose challenge
design was in a feasible range.
Impact of Animal-to-Animal Variation in Susceptibility
To study how potential heterogeneity in susceptibility
affected the power of low-dose challenge trials, we simulated
experiments in which each animal was assigned an individual
infection probability (see Methods). In these simulations, the
degree of heterogeneity was measured by the coefﬁcient of
variation, CV, of the susceptibility distributions. Figure 4A
shows susceptibility distributions for three different values of
CV.
We extended our power analysis by considering the impact
of the heterogeneity parameter CV on the statistical power
(Figure 4B). We found that the statistical power of the single
low-dose challenge design was almost unaffected by animal-
to-animal variation in infection probability, whereas, for the
repeated low-dose challenge design, the power decreased
with increasing heterogeneity. Importantly, however, the
power did not decrease linearly with heterogeneity: it was
sufﬁciently stable in the range 0 , CV , 0.3 and dropped
mainly for CV . 0.3. Thus, over a wide range of potential
animal-to-animal variation in susceptibility, low-dose chal-
Table 3. Outcome of One Virtual Repeated
Low-Dose Challenge Experiment
Number of Challenges
to Infect Control
Animals
Number of Challenges
to Infect Vaccinated
Animals
12 0
a
42 0
a
63
15
18
14
The vaccine is assumed to be 90% effective (VES¼0.9), i.e., the susceptibility of each animal to infection was reduced
from 0.5 to 0.05 by the vaccine. The table contains the numbers of challenges that were required to infect each of
the six animals in the control and vaccinated groups.
aThese two animals were not successfully infected after 20 challenges. Fisher’s exact test (one-sided) yields a p-value
of 0.002, i.e., this simulated experiment can successfully establish a treatment effect. The estimated vaccine efficacy
is VES¼0.85. To calculate the statistical power, we performed 100,000 such virtual experiments for differing numbers
of animals per group.
DOI: 10.1371/journal.pmed.0020249.t003
Figure 3. Impact of the Maximum Number of Challenges, Cmax, on the
Statistical Power
For this plot we assumed trials with vaccine efficacies of VES ¼ 0.67
(dotted line), VES ¼ 0.8 (dashed line), and VES ¼ 0.9 (solid line). In (A) we
calculated the statistical power for six animals per group, n¼6, and in (B)
for 12 animals per group, n ¼ 12.
DOI: 10.1371/journal.pmed.0020249.g003
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repeated low-dose experiments is superior to that of single
low-dose challenge experiments.
Discussion
Preclinical studies assessing the efﬁcacy of potential
vaccines, microbicides, or systemic chemoprophylaxis are
usually conducted with very high virus challenge doses, which
result in infection with certainty. Since these high challenge
doses do not reﬂect the low probability of HIV transmission
in humans, vaccines or prophylactic treatment strategies that
are effective against ‘‘real life’’ exposures may go undetected
in high-dose challenge experiments. For example, zidovudine
was found to prevent a large fraction of perinatal HIV
infections [23], even though studies in animal models,
conducted with high challenge doses, could not establish
any protection against infection by zidovudine [20–22].
In this paper, we investigated how efﬁcacy trials of vaccines
and preventive treatment could be conducted with low
challenge doses in animal models. We showed that the
repeated low-dose challenge design is expected to require
far fewer experimental animals than commonly believed. It
may therefore be feasible to conduct trials with low challenge
doses, which more realistically simulate exposures of humans
to HIV, allowing us to more directly and sensitively assess
vaccine or treatment efﬁcacy than with high-dose challenge
experiments.
Owing to the concerns with high challenge doses, several
research groups, including our own, have started to develop
low-dose challenge models [31–34]. In these preliminary
studies, infection could be achieved by challenging macaques
intra-rectally [31], intra-vaginally [32,34], or orally [33].
Since adopting low-dose challenge approaches has far-
reaching consequences for the design of efﬁcacy trials of
vaccines or preventive treatment in animal models, we would
like to discuss how some important aspects of trial design,
Figure 4. Impact of Heterogeneity in Susceptibility on the Statistical Power
(A) Susceptibility distributions for different levels of heterogeneity, measured by the coefficient of variation, CV, of the susceptibility distribution. The
vaccine is assumed to be 80% effective, VES ¼ 0.8.
(B) The statistical power depends on the coefficient of variation, CV, for the repeated low-dose challenge design (black lines) and the single low-dose
challenge design (green lines). For these plots we assumed trials with six and 12 animals per group and vaccine efficacies of VES¼0.67 (dotted lines), VES
¼ 0.8 (dashed lines), and VES ¼ 0.9 (solid lines).
DOI: 10.1371/journal.pmed.0020249.g004
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of infection, and the phenotype and dose of the challenge
strain, should be dealt with and could be optimized.
Using virus challenge doses that do not give rise to
infection with certainty, one has to carefully deﬁne what
one means by successful infection. This question is of
particular importance in the repeated low-dose challenge
design, because the efﬁcacy of a preventive intervention is
estimated on the basis of the number of challenges needed to
infect an individual animal. Low-dose challenges have been
observed to give rise to transiently detectable viremia [32–34].
Since transient infection is much more likely to lead to
immunization [35], thus leading to lower probabilities of
infection in subsequent challenges, we suggest considering
transient viremia as successful infection and not to re-
challenge animals that were transiently infected.
The time interval between challenges is also an essential
parameter in the design of repeated low-dose challenge
experiments. In the four ongoing repeated low-dose chal-
lenge studies [31–34], different approaches have been taken,
with time intervals ranging from hours to a week. There may
be logistical reasons for choosing short time intervals
between challenges, but from a statistical standpoint, the
time intervals should be large enough to allow the identi-
ﬁcation of the challenge that gives rise to infection.
Otherwise, the statistical power of the experimental design
will be suboptimal and a beneﬁcial effect of the vaccine
candidate may be missed.
In parallel to using more realistic, lower challenge doses,
other crucial parameters of the experimental infection
process, such as the route of transmission and the coreceptor
usage of the challenge virus, should also be chosen to be as
realistic as possible. Thus, we propose infecting intra-
vaginally or intra-rectally in experiments that aim to assess
a vaccine or prophylactic treatment against sexual trans-
mission of HIV. Further, we suggest using challenge viruses
that utilize CCR5 as coreceptor, such as for example SHIV-
SF162P [36], rather than the standard strain SHIV89.6P,
which has been found to use mainly CXCR4 [37,38]. These
more realistic choices of the route of infection and
coreceptor usage will permit the assessment of the efﬁcacy
of the preventive intervention in a setting that more
accurately reﬂects HIV exposures of humans, and will enable
us to carefully investigate the processes that give rise to
infection.
The challenge dose in a low-dose challenge study is another
parameter of crucial importance. Although the most realistic
choice would be a challenge dose that gives rise to infection
with a probability of approximately 0.0005–0.10 [14–17], such
extremely low doses would require unfeasibly large numbers
of repeated challenges per animal. Moreover, there is
substantial variation in transmission rates due to differences
in factors such as virus load or the presence of other
infections of the genital tract [15–18], and theoretical studies
suggest that preventing the transmission events that occur
with higher probability would have a disproportionately large
effect on controlling the epidemic [39]. To maximize their
epidemiological relevance, low-dose challenge experiments
should therefore involve challenge doses that reﬂect trans-
mission probabilities at the upper end of the spectrum. As a
compromise between the practicality of high doses and the
sensitivity associated with realistically low doses, we propose
the ID50. The ID50 can be estimated using well-established
nonparametric methods like Spearman-Ka ¨rber [40] or single-
parameter methods [41], and there is software available, such
as a freely distributed package called ID50 developed by John
Spouge (http://www.ncbi.nlm.nih.gov/CBBresearch/Spouge/
Virology/), which allows an automated estimation of the
ID50 from data generated in titration experiments.
The inability to detect sterilizing immunity in high-dose
challenge experiments led to a shift of focus towards indirect
effects of vaccine candidates on the pathogenicity of the
infection and the infectiousness of the vaccinee. This shift of
focus required the development of novel statistical models
that allowed the estimation of these indirect effects [42,43].
Will the estimation of vaccine efﬁcacy in repeated low-dose
challenge studies also require the development of novel
statistical techniques? The answer to this question depends
on how much the realities of the infection process deviate
from our idealized model. There are three potential devia-
tions. First, we assumed in large parts of this study that the
susceptibilities to infection were equal for all animals within
each group. This is almost certainly not the case. Although we
have shown that low-dose challenge experiments are sufﬁ-
ciently powered even if there is substantial animal-to-animal
variation in susceptibility, we did not develop the statistical
techniques that would allow the estimation of this variation.
The extent of animal-to-animal variation in susceptibility
can, in principle, be estimated, but this will probably require
larger numbers of animals than the estimation of vaccine
efﬁcacy. Second, the vaccine may affect the susceptibility of
individual animals differently. While we assumed in the
present study that the vaccine is leaky, i.e., that the
susceptibility is reduced by a constant factor in each animal,
other modes of action of a vaccine are possible. In particular,
some animals could be completely protected by vaccination,
while others may remain completely susceptible. This mode
of action is referred to as all-or-none [29,30]. Statistical
methods based on maximum likelihood approaches exist that
allow the determination of the mode of action of a given
vaccine. However, these methods are based on large sample
asymptotics, and exact methods will have to be developed to
analyze the outcome of low-dose challenge experiments that
involve small numbers of animals. Last, it will have to be
determined whether the probability of infection changes with
the number of challenges performed in a given animal, or, to
put it differently, whether the animal has a ‘‘memory’’ of
previous challenges. In our analysis, we assumed that the
susceptibility of an animal did not change from challenge to
challenge. If the probability of infection changes signiﬁcantly
with the number of challenges, however, the development of
novel statistical models that take such changes into account
will be necessary to adequately estimate vaccine efﬁcacy.
In addition to the potential to assess the vaccine or
microbicide efﬁcacy more sensitively and in a more realistic
setting, a low-dose challenge approach may enable us to
answer questions that cannot even be asked in high-dose
challenge models. Some of the most relevant of these
questions relate to the effect of challenges that do not lead
to infection. If a low-dose challenge does not give rise to
infection, where was the virus blocked? Did the virus fail to
establish an infection at all? Or did it replicate transiently,
but was cleared by the host’s immunity? And, very impor-
tantly, is an unsuccessfully challenged animal partially
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unsuccessful challenges facilitate future infection by ‘‘seed-
ing’’ animals with defective proviruses that may recombine
with complementing viruses upon subsequent exposures [44]?
The answers to these questions would greatly enhance our
understanding of HIV transmission and pathogenesis, and
thus would provide further guidance toward an effective
vaccine or microbicide. Furthermore, by assessing the
protection against infection directly, we may be able to
discern the speciﬁc types and levels of vaccine-induced
cellular and humoral immune responses associated with
sterilizing immunity [13]. This would provide important
benchmarks by which to judge new vaccine candidates, and
could also allow retrospective analysis of vaccine candidates
evaluated earlier in high-dose challenge studies.
In conclusion, the repeated low-dose challenge approach
may enable us to assess the potential efﬁcacy of vaccines and
prophylactic treatment strategies more realistically, and
more sensitively than the standard high-dose challenge
approach. The increased sensitivity may allow us to more
rapidly identify interventions that signiﬁcantly reduce the
transmission of low-dose infections that characterize the
natural spread of HIV.
Supporting Information
Protocol S1. R-Function for the Calculation of the Statistical Power of
Low-Dose Challenge Experiments
Found at DOI: 10.1371/journal.pmed.0020249.sd001 (8 KB TXT).
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Patient Summary
Background Before trials of medicines or vaccines are done in humans,
most are tested in animals. There are many controversies about these
animal trials, including whether they mimic the human disease
accurately. In testing vaccines for HIV, animals are mostly given high
doses of the virus, whereas in real life people are often repeatedly
exposed to small amounts of the virus. No vaccine that has been tested
against HIV prevents infection in animals. It is possible that some of this
lack of success may be due to the design of the vaccine trials rather than
the vaccine itself.
What Did the Authors Do? They wanted to look at experimental
designs that allowed assessment of protection against infection with
lower, and thus more realistic, doses of virus. Previously, researchers had
suggested that many animals would be needed for this type of study.
The authors wanted to see whether this was correct. They developed a
model to test how well single and multiple low-dose experiments
performed. They did this by simulating the experiments with doses of
virus, assessing the results, and then repeating this procedure 100,000
times to estimate how valid a given experimental design was.
Their modeling showed that by repeatedly giving animals low doses of
virus, it was possible to use a smaller number of animals than was
needed for trials with a single low dose.
What Do These Results Mean? It may be possible to use these results
to plan trials of vaccines in animals that mimic more closely the way that
humans are exposed to HIV, and hence the results may be more reliable
for human disease.
Where Can I Get More Information? MedlinePlus has a great deal of
information on HIV:
http://www.nlm.nih.gov/medlineplus/aids.html
The Body has information targeted to both patients and health
professionals:
http://www.thebody.com/index.shtml
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